SurModics, Inc. (SRDX) Hits New 12-Month High at $28.74
SurModics, Inc. (NASDAQ:SRDX) shares hit a new 52-week high on Tuesday . The stock traded as high as $28.74 and last traded at $28.65, with a volume of 27,425 shares. The stock had previously closed at $27.83.
Several analysts have recently commented on SRDX shares. Zacks Investment Research upgraded shares of SurModics from a “hold” rating to a “strong-buy” rating and set a $27.00 price target on the stock in a research report on Wednesday, May 4th. Barrington Research increased their price target on shares of SurModics from $27.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, May 3rd. Finally, TheStreet upgraded shares of SurModics from a “hold” rating to a “buy” rating in a research report on Tuesday, April 26th.
The firm has a market cap of $370.61 million and a price-to-earnings ratio of 42.47. The company’s 50 day moving average is $25.24 and its 200-day moving average is $21.62.
SurModics (NASDAQ:SRDX) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.37 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.12 by $0.25. During the same quarter in the prior year, the business earned $0.30 earnings per share. The firm earned $19.97 million during the quarter, compared to the consensus estimate of $16.31 million. The company’s revenue for the quarter was up 25.6% compared to the same quarter last year. Equities research analysts predict that SurModics, Inc. will post $1.04 EPS for the current fiscal year.
In related news, SVP Bryan K. Phillips sold 1,816 shares of SurModics stock in a transaction dated Tuesday, June 14th. The shares were sold at an average price of $23.44, for a total value of $42,567.04. Following the sale, the senior vice president now directly owns 25,350 shares in the company, valued at approximately $594,204. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Charles W. Olson sold 12,500 shares of SurModics stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $27.08, for a total transaction of $338,500.00. Following the completion of the sale, the vice president now owns 35,531 shares in the company, valued at $962,179.48. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in SurModics stock. Dimensional Fund Advisors LP boosted its stake in shares of SurModics, Inc. (NASDAQ:SRDX) by 0.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 515,134 shares of the company’s stock after buying an additional 1,970 shares during the period. Dimensional Fund Advisors LP owned 3.96% of SurModics worth $10,442,000 at the end of the most recent quarter.
SurModics, Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.